Abstract: Tumor necrosis factor-related apoptosis-inducing ligand receptor（TRAIL-R）， one of important binding targets of TRAIL-mediated apoptosis， including TRAIL-R1 and TRAIL-R2（ie， death receptor 4 and death receptor 5） not only directly relates to the induction of apoptosis receptors， but also one of the most promising targets for drug design. We carried out a comprehensive review of these antibodies’preclinical and clinical studies to explore the TRAIL-mediated anti-tumor therapy and provide references for further study.